Last updated on April 2020

CLARITY 2 - Depression Research Study: Adjunctive Treatment of Major Depressive Disorder

Brief description of study

Summit Research Network is enrolling participants in an investigational medication research study for Major Depressive Disorder.  The purpose of this study is to  evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have  inadequate response to antidepressant therapy. 

Qualified participants may be involved for up to 14 weeks and visit the research center 8 times.  At the first visit, qualified participants will enter a screening period. After the initial screening period participants will receive either the investigational medication or a placebo (an inactive substance) for up to 6 weeks and visit the research center weekly.  Thirty days after the last dose of theinvestigational medication, participants will complete a follow-up visit by phone.


Clinical Study Identifier: TX224556

Find a site near you

Start Over

Summit Research Network, Inc.

2701 NW Vaughn Street, Suite 350 Portland, OR USA
  Connect »